Vol 7: Low dose of interferon- improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study.Report as inadecuate



 Vol 7: Low dose of interferon- improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study.


Vol 7: Low dose of interferon- improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 7: Low dose of interferon- improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study.
This article is from Oncology Letters, volume 7.AbstractThe aim of this study was to test whether a low dose of interferon-α-2b IFN-α2b enhances the clinical outcome of docetaxel DXT in patients with castration-resistant prostate cancer CRPC. A prospective controlled trial of 40 CRPC patients receiving 5 mg of prednisone twice daily was conducted, where patients were randomly assigned to be administered 75 mg-m2 DXT plus 3 mIU-m2 IFN-α2b group A, n=20 or 75 mg-m2 DXT alone group B, n=20. The prostate-specific antigen PSA response, tumor response, progression-free survival PFS and overall survival OS were evaluated. There was no statistically significant difference in PSA response rate between groups A and B 65 vs. 47.4%, P=0.341. The tumor response rate in group A was significantly greater compared with that in group B 55 vs. 21.1%, P=0.048. The median PFS was longer in group A compared with that in group B 10 vs. 8 months, P=0.043. There was no statistically significant difference in median OS between the two groups 19 vs. 17 months, P=0.348, but one patient displayed a complete tumor response in group A. In groups A and B, transient grade 3 to 4 neutropenia was observed in nine and six patients, grade 3 to 4 anemia was observed in three and five patients, and grade 3 to 4 general fatigue was observed in four and one patients, respectively. The proportion of patients with grade 3 to 4 toxicity was not statistically different between the two groups. A low dosage of IFN-α2b may improve the antitumor activity of DXT with an acceptable toxicity profile in patients with CRPC.



Author: LI, YUN-FEI; WANG, QIN-ZHANG; ZHANG, TAO-TAO; LI, LEI; WANG, JIANG-PING; DING, GUO-FU; HE, DA-LIN

Source: https://archive.org/



DOWNLOAD PDF




Related documents